Heron Therapeutics Inc. (NASDAQ:HRTX) dropped 4.4% on Monday . The stock traded as low as $16.36 and last traded at $16.40, with a volume of 228,324 shares trading hands. The stock had previously closed at $17.16.

HRTX has been the subject of several recent research reports. Cowen and Company reissued a “buy” rating and issued a $47.00 price target on shares of Heron Therapeutics in a research note on Sunday, April 17th. Leerink Swann reissued a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, April 19th. Brean Capital reissued a “buy” rating on shares of Heron Therapeutics in a research note on Monday, April 18th. Jefferies Group reissued a “buy” rating on shares of Heron Therapeutics in a research note on Monday, April 18th. Finally, Noble Financial reissued a “buy” rating and issued a $51.00 price target on shares of Heron Therapeutics in a research note on Wednesday, April 20th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $51.50.

The company has a 50 day moving average of $18.59 and a 200-day moving average of $19.68.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.92) EPS for the quarter, hitting analysts’ consensus estimates of ($0.92). On average, equities research analysts forecast that Heron Therapeutics Inc. will post ($3.59) EPS for the current fiscal year.

In related news, President Robert Rosen sold 200,000 shares of the stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $23.23, for a total value of $4,646,000.00. Following the transaction, the president now owns 178,968 shares in the company, valued at $4,157,426.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Other institutional investors recently made changes to their positions in the company. Russell Frank Co increased its position in shares of Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock valued at $1,369,000 after buying an additional 15,585 shares during the period. California State Teachers Retirement System increased its position in shares of Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares during the period. Swiss National Bank bought a new position in shares of Heron Therapeutics during the fourth quarter valued at approximately $1,100,000. California Public Employees Retirement System increased its position in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 81,200 shares during the period. Finally, Brown Advisory Inc. increased its position in shares of Heron Therapeutics by 4.8% in the fourth quarter. Brown Advisory Inc. now owns 300,941 shares of the biotechnology company’s stock valued at $8,036,000 after buying an additional 13,651 shares during the period.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.